Trials / Completed
CompletedNCT00704132
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
A Randomized, Placebo-Controlled Study to Evaluate the Safety, Efficacy and Mechanism of Action of MK0431/Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Comparator: sitagliptin phosphate | Sitagliptin tablet 100 mg, administered once daily before the morning meal. |
| DRUG | Comparator: placebo (unspecified) | Matching placebo tablet, administered once daily before the morning meal. |
Timeline
- Start date
- 2007-02-14
- Primary completion
- 2010-04-28
- Completion
- 2010-04-28
- First posted
- 2008-06-24
- Last updated
- 2017-05-12
- Results posted
- 2011-05-16
Source: ClinicalTrials.gov record NCT00704132. Inclusion in this directory is not an endorsement.